Abstract
Major depression is one of the most prevalent neuropsychological disorders and affects millions worldwide. In response, the monoaminergic system has been proposed to be one of the major focuses for conventional drugs in the treatment of depression, such as selective serotonin reuptake inhibitor (SSRI). Meanwhile, accumulating evidence suggests a paradigm shift from the monoamine system towards the glutamatergic system (Gerard Sanacora, Giulia Treccani, and Maurizio Popoli 2012) due to the long onset of the monoamine system targeting anti-depressant drugs. Both clinical and pre-clinical data support that glutamatergic system dysfunction were involved in the development of depression. Furthermore, therapeutic approaches that manipulating neuronal activity and N-methyl-D-aspartic acid (NMDA) receptor antagonist were shown to have profound effects in the treatment of depression. Here, I systematically reviewed our current understanding of the involvement of glutamatergic system dysregulation in the development of depression, which potentially could provide the mechanistic basis for future treatment development.